SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Weikang Bio-Technology Group Co., Inc. – ‘10-K’ for 12/31/11 – ‘EX-31.2’

On:  Friday, 3/30/12, at 3:12pm ET   ·   For:  12/31/11   ·   Accession #:  1144204-12-18721   ·   File #:  333-165684

Previous ‘10-K’:  ‘10-K/A’ on 12/28/11 for 12/31/10   ·   Latest ‘10-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/12  Weikang Bio-Tech Group Co., Inc.  10-K       12/31/11   44:2.3M                                   Toppan Merrill/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    474K 
 2: EX-10.12    Material Contract                                   HTML     15K 
 3: EX-14.1     Code of Ethics                                      HTML     26K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     14K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     13K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     19K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     19K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     15K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
28: R1          Document and Entity Information                     HTML     45K 
21: R2          Consolidated Balance Sheets                         HTML    128K 
26: R3          Consolidated Balance Sheets (Parenthetical)         HTML     25K 
30: R4          Consolidated Statements of Income and               HTML     99K 
                Comprehensive Income                                             
41: R5          Consolidated Statements of Cash Flows               HTML    111K 
22: R6          Consolidated Statements of Stockholders' Equity     HTML     64K 
25: R7          Organization and Description of Business            HTML     26K 
20: R8          Summary of Significant Accounting Policies          HTML     65K 
18: R9          Accounts Receivable                                 HTML     22K 
42: R10         Advances to Suppliers and Other Receivables         HTML     17K 
32: R11         Inventory                                           HTML     20K 
31: R12         Property and Equipment, net                         HTML     23K 
36: R13         Construction in Progress                            HTML     15K 
37: R14         Intangible Assets                                   HTML     21K 
35: R15         Related Party Transactions                          HTML     20K 
38: R16         Major Customers and Vendors                         HTML     15K 
27: R17         Unearned Revenue                                    HTML     18K 
29: R18         Taxes Payable                                       HTML     17K 
34: R19         Other Payables and Accrued Expenses                 HTML     18K 
44: R20         Deferred Tax Asset (Liability)                      HTML     19K 
39: R21         Income Taxes                                        HTML     26K 
23: R22         Stockholders' Equity                                HTML     62K 
33: R23         Statutory Reserves                                  HTML     18K 
24: R24         Contingencies                                       HTML     16K 
16: R25         Goodwill                                            HTML     16K 
40: R26         Subsequent Event                                    HTML     16K 
43: XML         IDEA XML File -- Filing Summary                      XML     53K 
19: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    212K 
10: EX-101.INS  XBRL Instance -- wkbt-20111231                       XML    314K 
12: EX-101.CAL  XBRL Calculations -- wkbt-20111231_cal               XML    105K 
13: EX-101.DEF  XBRL Definitions -- wkbt-20111231_def                XML    300K 
14: EX-101.LAB  XBRL Labels -- wkbt-20111231_lab                     XML    341K 
15: EX-101.PRE  XBRL Presentations -- wkbt-20111231_pre              XML    348K 
11: EX-101.SCH  XBRL Schema -- wkbt-20111231                         XSD     60K 
17: ZIP         XBRL Zipped Folder -- 0001144204-12-018721-xbrl      Zip     56K 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Baolin Sun, certify that:

 

1. I have reviewed this annual report on Form 10-K of Weikang Bio-Technology Group Co., Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Dated: March 30, 2012 By: /s/ Baolin Sun
   

Baolin Sun

Chief Financial Officer

 

 C: 
 


Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/30/12None on these Dates
For Period end:12/31/11
 List all Filings 
Top
Filing Submission 0001144204-12-018721   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 10:38:15.0am ET